Literature DB >> 30652474

Investigation of ( S)-(-)-Acidomycin: A Selective Antimycobacterial Natural Product That Inhibits Biotin Synthase.

Matthew R Bockman1, Curtis A Engelhart2, Julia D Cramer3, Michael D Howe1, Neeraj K Mishra1, Matthew Zimmerman4, Peter Larson1, Nadine Alvarez-Cabrera4, Sae Woong Park2, Helena I M Boshoff5, James M Bean6, Victor G Young7, David M Ferguson1, Veronique Dartois4, Joseph T Jarrett3, Dirk Schnappinger2, Courtney C Aldrich1.   

Abstract

The synthesis, absolute stereochemical configuration, complete biological characterization, mechanism of action and resistance, and pharmacokinetic properties of ( S)-(-)-acidomycin are described. Acidomycin possesses promising antitubercular activity against a series of contemporary drug susceptible and drug-resistant M. tuberculosis strains (minimum inhibitory concentrations (MICs) = 0.096-6.2 μM) but is inactive against nontuberculosis mycobacteria and Gram-positive and Gram-negative pathogens (MICs > 1000 μM). Complementation studies with biotin biosynthetic pathway intermediates and subsequent biochemical studies confirmed acidomycin inhibits biotin synthesis with a Ki of approximately 1 μM through the competitive inhibition of biotin synthase (BioB) and also stimulates unproductive cleavage of S-adenosyl-l-methionine (SAM) to generate the toxic metabolite 5'-deoxyadenosine. Cell studies demonstrate acidomycin selectively accumulates in M. tuberculosis providing a mechanistic basis for the observed antibacterial activity. The development of spontaneous resistance by M. tuberculosis to acidomycin was difficult, and only low-level resistance to acidomycin was observed by overexpression of BioB. Collectively, the results provide a foundation to advance acidomycin and highlight BioB as a promising target.

Entities:  

Keywords:  Mycobacterium tuberculosis; accumulation; acidomycin; antimetabolite; biotin biosynthesis; biotin synthase; tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 30652474      PMCID: PMC6724193          DOI: 10.1021/acsinfecdis.8b00345

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  75 in total

1.  [Further studies on potentiation of inhibitor action through determination of reversing metabolites].

Authors:  T B STIM; B C ARNWINE; J W FOSTER
Journal:  J Bacteriol       Date:  1959-05       Impact factor: 3.490

2.  Thiazolidone antibiotic as an antimetabolite to biotin.

Authors:  H UMEZAWA; K OIKAWA; Y OKAMI; K MAEDA
Journal:  J Bacteriol       Date:  1953-07       Impact factor: 3.490

3.  Construction of conditional knockdown mutants in mycobacteria.

Authors:  Dirk Schnappinger; Kathryn M O'Brien; Sabine Ehrt
Journal:  Methods Mol Biol       Date:  2015

4.  [2Fe-2S] to [4Fe-4S] cluster conversion in Escherichia coli biotin synthase.

Authors:  E C Duin; M E Lafferty; B R Crouse; R M Allen; I Sanyal; D H Flint; M K Johnson
Journal:  Biochemistry       Date:  1997-09-30       Impact factor: 3.162

5.  Purification, Characterization, and Biochemical Assays of Biotin Synthase From Escherichia coli.

Authors:  Julia D Cramer; Joseph T Jarrett
Journal:  Methods Enzymol       Date:  2018-07-09       Impact factor: 1.600

6.  Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.

Authors:  S E David; P Timmins; B R Conway
Journal:  Drug Dev Ind Pharm       Date:  2012-01       Impact factor: 3.225

7.  Iron-sulfur cluster interconversions in biotin synthase: dissociation and reassociation of iron during conversion of [2Fe-2S] to [4Fe-4S] clusters.

Authors:  N B Ugulava; B R Gibney; J T Jarrett
Journal:  Biochemistry       Date:  2000-05-02       Impact factor: 3.162

Review 8.  Biotin synthase: insights into radical-mediated carbon-sulfur bond formation.

Authors:  Corey J Fugate; Joseph T Jarrett
Journal:  Biochim Biophys Acta       Date:  2012-01-28

9.  Characterization of the cofactor composition of Escherichia coli biotin synthase.

Authors:  Michele Mader Cosper; Guy N L Jameson; Heather L Hernández; Carsten Krebs; Boi Hanh Huynh; Michael K Johnson
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

10.  A potent IκB kinase-β inhibitor labeled with carbon-14 and deuterium.

Authors:  Bachir Latli; Magnus Eriksson; Matt Hrapchak; Carl A Busacca; Chris H Senanayake
Journal:  J Labelled Comp Radiopharm       Date:  2016-04-13       Impact factor: 1.921

View more
  4 in total

1.  Development of small-molecule inhibitors of fatty acyl-AMP and fatty acyl-CoA ligases in Mycobacterium tuberculosis.

Authors:  Marzena Baran; Kimberly D Grimes; Paul A Sibbald; Peng Fu; Helena I M Boshoff; Daniel J Wilson; Courtney C Aldrich
Journal:  Eur J Med Chem       Date:  2020-06-13       Impact factor: 6.514

2.  A small-molecular inhibitor against Proteus mirabilis urease to treat catheter-associated urinary tract infections.

Authors:  Scarlet Milo; Rachel A Heylen; John Glancy; George T Williams; Bethany L Patenall; Hollie J Hathaway; Naing T Thet; Sarah L Allinson; Maisem Laabei; A Toby A Jenkins
Journal:  Sci Rep       Date:  2021-02-12       Impact factor: 4.379

3.  Screening of Microbial Fermentation Products for Anti-M. tuberculosis Activity.

Authors:  Aikebaier Reheman; Di Lu; Yifan Wang; Xi Chen; Gang Cao; Chuanxing Wan
Journal:  Animals (Basel)       Date:  2022-07-31       Impact factor: 3.231

4.  Mimicking the human environment in mice reveals that inhibiting biotin biosynthesis is effective against antibiotic-resistant pathogens.

Authors:  Lindsey A Carfrae; Craig R MacNair; Christopher M Brown; Caressa N Tsai; Brent S Weber; Soumaya Zlitni; Vishwas N Rao; Joshua Chun; Murray S Junop; Brian K Coombes; Eric D Brown
Journal:  Nat Microbiol       Date:  2019-10-28       Impact factor: 30.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.